ABCMdb

ABCG2 p.Cys43Ala

None has been submitted yet.

Publications

PMID: 18430864 [PubMed] Liu Y et al: "Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2."

No. Sentence Comment

111 Mutation of one or two of these residues (I2-CL, C284A, and C374A) did not signifi- TABLE 1 Primers used for construction of cysless mutants Mutations Primer Sequence RESa C43A TTTCATAACATTGCCTATCGAGTAAAACTGAAG BsrDI C55A GCTTTCTACCTGCACGAAAACCAGTTGAG BsgI C119A GCCAATTTCAAAGCGAATTCAGGTTACGTGG EcoRI C284A GAATCAGCTGGATATCACGCTGAGGCCTATAATAAC EcoRV C374A ACACCACCTCCTTCGCTCATCAACTCAGATG None C438A CTGACGACCAACCAAGCTTTCAGCAGTGTTTC HindIII C491A TATATTTACCGCTATAGTATACTTCATGTTAGG AccI C544A CTTCTCATGACGATCGCTTTTGTGTTTATGATG PvuI C592A GGACAAAACTTCGCCCCGGGACTCAATGCAA SmaI C603A/C608A AGGAAACAATCCTGCTAACTATGCAACAGCTACTGGCGAAGAATATTT -NspI C635A CACGTGGCCTTGGCTGCAATGATTGTTATTTTC BsrDI a Restriction (RES) enzyme digestion sites engineered in the primer for the convenience of detection. Login to comment

PMID: 20922799 [PubMed] Tanaka M et al: "Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome."

No. Sentence Comment

88 Overall Survival by Genotype Genotype No. of Patients No. of Deaths MST6SE (Months) Log-Rank P HRa (95% CI) P MDR1 T-55C CC 45 32 23.8Æ5.3 CT 64 46 21.5Æ3.3 TT 43 31 21.7Æ3.4 .982 CC vs TT/CT .869 1.24 (0.81-1.90) .317 MRP1 G36A GG 81 64 21.5Æ2.4 AG 60 38 23.9Æ9.3 AA 13 9 21.4Æ6.1 .247 AA/AG vs GG .136 1.03 (0.69-1.53) .890 MRP2 G40A GG 86 67 21.2Æ2.6 AG 55 34 31.0Æ7.1 AA 10 7 17.5Æ4.8 .172 AG/AA vs GG .097 1.55 (1.02-2.36) .040 MRP2 C-16T CC 63 44 23.9Æ4.2 CT 69 49 20.7Æ4.0 TT 19 15 22.5Æ2.2 .962 CC vs TT/CT .785 1.13 (0.75-1.69) .557 MRP3 C-13T CC 89 67 21.4Æ2.3 CT 47 32 28.7Æ7.0 TT 13 8 23.9Æ10.9 .307 CT/TT vs CC .129 1.10 (0.72-1.67) .664 MRP4 A40G GG 54 34 26.4Æ8.1 AG 76 58 21.7Æ2.4 AA 22 17 14.6Æ2.6 .172 GG/AG vs AA .158 1.29 (0.75-2.23) .357 MRP5 A-2G AA 68 54 18.4Æ3.0 AG 62 38 31.0Æ4.2 GG 22 17 20.7Æ7.0 .017 AG/GG vs AA .010 1.65 (1.11-2.45) .013 BCRP C43A CC 116 83 23.9Æ3.3 AC 27 19 21.2Æ0.8 AA 4 3 20.4Æ10.0 .960 AA/AC vs CC .960 1.05 (0.65-1.72) .834 No. of deleterious allelesb .006 0 39 21 34.0Æ12.0 1-2 112 87 20.7Æ1.5 2.18 (1.32-3.60) .002 MST, median survival time; SE, standard error; HR, Hazard ratio a HR was adjusted for history of diabetes, tumor size, serum level of CA19-9, tumor response, and tumor resection. Login to comment
116 Although MDR1 T-55C and BCRP C43A were reported to be functional SNPs that change their protein functions,25,29 none of these SNPs-nor the MRP1, MRP3, or MRP4 gene SNPs examined in this study-had any association with overall survival or tumor response to therapy. Login to comment